Cargando…

Clinical characteristics of Japanese patients with moderate to severe COVID-19

INTRODUCTION: Although several reports on the risk factors for severe disease of COVID-19 already exist, reports on effective early indicators are still limited, especially from Japan. This study was conducted to clarify the patient’s characteristics whose disease progressed to severe status. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Otoshi, Ryota, Hagiwara, Eri, Kitayama, Takaaki, Yamaya, Takafumi, Higa, Katsuyuki, Murohashi, Kota, Sato, Yozo, Tabata, Erina, Shintani, Ryota, Okabayashi, Hiroko, Ikeda, Satoshi, Niwa, Takashi, Nakazawa, Atsuhito, Oda, Tsuneyuki, Okuda, Ryo, Sekine, Akiamasa, Kitamura, Hideya, Baba, Tomohisa, Komatsu, Shigeru, Ogura, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931728/
https://www.ncbi.nlm.nih.gov/pubmed/33727024
http://dx.doi.org/10.1016/j.jiac.2021.02.028
_version_ 1783660349553115136
author Otoshi, Ryota
Hagiwara, Eri
Kitayama, Takaaki
Yamaya, Takafumi
Higa, Katsuyuki
Murohashi, Kota
Sato, Yozo
Tabata, Erina
Shintani, Ryota
Okabayashi, Hiroko
Ikeda, Satoshi
Niwa, Takashi
Nakazawa, Atsuhito
Oda, Tsuneyuki
Okuda, Ryo
Sekine, Akiamasa
Kitamura, Hideya
Baba, Tomohisa
Komatsu, Shigeru
Ogura, Takashi
author_facet Otoshi, Ryota
Hagiwara, Eri
Kitayama, Takaaki
Yamaya, Takafumi
Higa, Katsuyuki
Murohashi, Kota
Sato, Yozo
Tabata, Erina
Shintani, Ryota
Okabayashi, Hiroko
Ikeda, Satoshi
Niwa, Takashi
Nakazawa, Atsuhito
Oda, Tsuneyuki
Okuda, Ryo
Sekine, Akiamasa
Kitamura, Hideya
Baba, Tomohisa
Komatsu, Shigeru
Ogura, Takashi
author_sort Otoshi, Ryota
collection PubMed
description INTRODUCTION: Although several reports on the risk factors for severe disease of COVID-19 already exist, reports on effective early indicators are still limited, especially from Japan. This study was conducted to clarify the patient’s characteristics whose disease progressed to severe status. METHODS: The medical records of all consecutive 300 Japanese patients hospitalized at our institution between February and November 2020 were retrospectively reviewed. The clinical characteristics were evaluated to compare between mild (no oxygen needed), moderate (oxygen needs of 1–4 L/min), and severe diseases (oxygen needs of 5 L/min or more). RESULTS: The median age was 68 years old, with 123 (41.0%) males and 177 (59.0%) females. Of these, 199 patients (66.3%), 55 patients (18.3%), 46 patients (15.3%) patients were in the mild disease, moderate disease, severe disease groups, respectively. Patients with severe disease were more likely to be older, have more comorbidities, and tended to have higher body mass index. In laboratory data, lymphocyte count, levels of C-reactive protein (CRP), LDH, and AST on admission were significantly associated with the severity. In multivariate analysis, age and CRP were the independent risk factors for severe disease (OR = 1.050, 1.130, respectively). The optimal cut-off value for age was 74 years old and that for CRP was 3.15 mg/dL. CONCLUSIONS: Age and CRP were independently associated with disease severity of COVID-19 in multivariate analysis. Additionally, the numbers of underlying disease, lymphocyte count, and inflammatory markers such as LDH and D-dimer may also be related to disease severity.
format Online
Article
Text
id pubmed-7931728
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-79317282021-03-05 Clinical characteristics of Japanese patients with moderate to severe COVID-19 Otoshi, Ryota Hagiwara, Eri Kitayama, Takaaki Yamaya, Takafumi Higa, Katsuyuki Murohashi, Kota Sato, Yozo Tabata, Erina Shintani, Ryota Okabayashi, Hiroko Ikeda, Satoshi Niwa, Takashi Nakazawa, Atsuhito Oda, Tsuneyuki Okuda, Ryo Sekine, Akiamasa Kitamura, Hideya Baba, Tomohisa Komatsu, Shigeru Ogura, Takashi J Infect Chemother Original Article INTRODUCTION: Although several reports on the risk factors for severe disease of COVID-19 already exist, reports on effective early indicators are still limited, especially from Japan. This study was conducted to clarify the patient’s characteristics whose disease progressed to severe status. METHODS: The medical records of all consecutive 300 Japanese patients hospitalized at our institution between February and November 2020 were retrospectively reviewed. The clinical characteristics were evaluated to compare between mild (no oxygen needed), moderate (oxygen needs of 1–4 L/min), and severe diseases (oxygen needs of 5 L/min or more). RESULTS: The median age was 68 years old, with 123 (41.0%) males and 177 (59.0%) females. Of these, 199 patients (66.3%), 55 patients (18.3%), 46 patients (15.3%) patients were in the mild disease, moderate disease, severe disease groups, respectively. Patients with severe disease were more likely to be older, have more comorbidities, and tended to have higher body mass index. In laboratory data, lymphocyte count, levels of C-reactive protein (CRP), LDH, and AST on admission were significantly associated with the severity. In multivariate analysis, age and CRP were the independent risk factors for severe disease (OR = 1.050, 1.130, respectively). The optimal cut-off value for age was 74 years old and that for CRP was 3.15 mg/dL. CONCLUSIONS: Age and CRP were independently associated with disease severity of COVID-19 in multivariate analysis. Additionally, the numbers of underlying disease, lymphocyte count, and inflammatory markers such as LDH and D-dimer may also be related to disease severity. Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2021-06 2021-03-04 /pmc/articles/PMC7931728/ /pubmed/33727024 http://dx.doi.org/10.1016/j.jiac.2021.02.028 Text en © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Otoshi, Ryota
Hagiwara, Eri
Kitayama, Takaaki
Yamaya, Takafumi
Higa, Katsuyuki
Murohashi, Kota
Sato, Yozo
Tabata, Erina
Shintani, Ryota
Okabayashi, Hiroko
Ikeda, Satoshi
Niwa, Takashi
Nakazawa, Atsuhito
Oda, Tsuneyuki
Okuda, Ryo
Sekine, Akiamasa
Kitamura, Hideya
Baba, Tomohisa
Komatsu, Shigeru
Ogura, Takashi
Clinical characteristics of Japanese patients with moderate to severe COVID-19
title Clinical characteristics of Japanese patients with moderate to severe COVID-19
title_full Clinical characteristics of Japanese patients with moderate to severe COVID-19
title_fullStr Clinical characteristics of Japanese patients with moderate to severe COVID-19
title_full_unstemmed Clinical characteristics of Japanese patients with moderate to severe COVID-19
title_short Clinical characteristics of Japanese patients with moderate to severe COVID-19
title_sort clinical characteristics of japanese patients with moderate to severe covid-19
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931728/
https://www.ncbi.nlm.nih.gov/pubmed/33727024
http://dx.doi.org/10.1016/j.jiac.2021.02.028
work_keys_str_mv AT otoshiryota clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT hagiwaraeri clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT kitayamatakaaki clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT yamayatakafumi clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT higakatsuyuki clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT murohashikota clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT satoyozo clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT tabataerina clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT shintaniryota clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT okabayashihiroko clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT ikedasatoshi clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT niwatakashi clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT nakazawaatsuhito clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT odatsuneyuki clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT okudaryo clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT sekineakiamasa clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT kitamurahideya clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT babatomohisa clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT komatsushigeru clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19
AT oguratakashi clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19